Archive for Friday, June 30, 2006

Panel supports cervical cancer vaccine for girls

June 30, 2006


— A federal public health advisory panel on Thursday recommended that girls ages 11 and 12 be routinely vaccinated against a common sexually transmitted disease that can lead to cervical cancer.

The Advisory Committee on Immunization Practices unanimously endorsed the widespread use of Gardasil, a Merck & Co. vaccine that received approval from the Food and Drug Administration this month for females ages 9 to 26.

The committee's recommendations generally are accepted by federal and state policymakers, which means Gardasil likely will be added to the list of vaccinations routinely administered to children.

In addition, the committee, an arm of the Centers for Disease Control and Prevention, said females ages 13 to 26 who have not been vaccinated against cervical cancer should be treated with Gardasil, and that girls as young as 9 could receive the medicine at their doctor's discretion.

"This is a historic vote : and a huge breakthrough for women's health," said Dr. Anne Schuchat, director of the National Center for Immunizations and Respiratory Diseases, at a news conference.

Cervical cancer is the second most lethal form of cancer worldwide. In the U.S., nearly 10,000 cases are diagnosed each year and about 3,700 deaths are attributed to the disease, according to the CDC.

Schuchat said the committee also addressed concerns that the vaccination might be too expensive for some by recommending that it be provided free to children who are eligible for Medicaid or uninsured.

Gardasil, one of the most expensive vaccines on the market, is administered in three doses over a six-month period, with each dose costing $120.

Schuchat reiterated earlier statements by Merck and the FDA, stressing that Gardasil has proved most effective when administered to women before they become sexually active.

Religious conservatives initially balked at the idea of giving the vaccine to adolescent girls, suggesting it could promote promiscuity. But those concerns have subsided as health officials have broadly endorsed the vaccination.

Gardasil is effective only as a preventative treatment, according to Schuchat, and cannot be used against existing cases of cervical cancer.

Merck said shipments of the vaccine were on their way to pediatricians' offices and would be available any day now.

Gardasil works by targeting four types of a common sexually transmitted disease called human papillomavirus, or HPV, which causes most cervical cancers and genital warts.

The National Institutes of Health estimates that 20 million people are infected with HPV, making it one of the most common forms of sexually transmitted diseases.

In approving Gardasil, the FDA said the vaccine had proved effective against the two strains of HPV that cause 70 percent of cervical cancers, as well as the two strains that cause 90 percent of genital warts.

The Advisory Committee on Immunization Practices is made up of independent specialists who report their findings to the U.S. Department of Health and Human Services. The American Academy of Pediatrics uses the recommendations in adopting guidelines for standard practice, and insurance providers rely on the findings to decide on coverage.


Use the comment form below to begin a discussion about this content.

Commenting has been disabled for this item.